Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06824701 · ClinicalTrials.gov registry record · Phase 1
Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
A Phase 1 study of Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, sponsored by University of Utah.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT06824701 is a Phase 1 study of Relapsed or Refractory B Cell Non-Hodgkin Lymphoma that is actively recruiting participants, run by University of Utah. The registered enrollment target is 24 participants, roughly in line with the 26-participant average among 3 other Relapsed or Refractory B Cell Non-Hodgkin Lymphoma trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT06824701, a Phase 1 study of Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, is actively recruiting participants, sponsored by University of Utah.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this clinical trial is to learn if the study drug Tazemetostat combined with Zanubrutinib and anti-CD20 monoclonal antibody is safe and effective in treating patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma.
Conditions Studied
Interventions
- DRUG Zanubrutinib
- DRUG Obinutuzumab
- DRUG Rituximab
- DRUG Tazemetostat
Study Locations (1)
Utah
- Huntsman Cancer Institute at University of Uta - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-09-12 |
| Est. Completion | 2033-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06824701
The ClinicalTrials.gov registry entry for NCT06824701 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 26-participant average among 3 other Relapsed or Refractory B Cell Non-Hodgkin Lymphoma trials with a reported enrollment target. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Zanubrutinib is the first listed.
NCT06824701 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.
Frequently Asked Questions
What is clinical trial NCT06824701 about?
NCT06824701 is a clinical study titled "Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma". The purpose of this clinical trial is to learn if the study drug Tazemetostat combined with Zanubrutinib and anti-CD20 monoclonal antibody is safe and effective in treating patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma.
What is the current status of trial NCT06824701?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2025-09-12. Estimated completion is 2033-01.
What conditions does trial NCT06824701 study?
This clinical trial studies the following conditions: Relapsed or Refractory B Cell Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT06824701?
The interventions under investigation include: Zanubrutinib (DRUG), Obinutuzumab (DRUG), Rituximab (DRUG), Tazemetostat (DRUG).
Who is sponsoring clinical trial NCT06824701?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06824701 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
RECRUITING · Phase 1
-
A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)
ACTIVE NOT RECRUITING · Phase 1
-
Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.